By What Percentage Did J&J’s Revenue & EBITDA Grow In The Last 5 Years?
- 14% Revenue Growth Driven By Immunology & Cancer Drugs
- 20% EBITDA Growth Driven By Revenue Increase And Margin Expansion
Relevant Articles
- Here’s What To Expect From Johnson & Johnson’s Q1
- What’s Next For Johnson & Johnson Stock After A 6% Decline In A Month?
- Is Johnson & Johnson Stock A Better Pick Over AbbVie?
- Will Johnson & Johnson Stock Rebound To Its Pre-Inflation Shock Highs of $185?
- Should You Pick Johnson & Johnson Stock At $160?
- Should You Pick Johnson & Johnson Stock After A 6% Fall In A Month Despite Upbeat Q3?
Have more questions about Johnson & Johnson? See the links below.
- How J&J’s Increased Focus On Pharmaceuticals Has Helped Its Financials?
- Drugs, Devices, Consumer: What’s Johnson & Johnson’s Revenue and Earnings breakdown?
- What’s J&J’s Fundamental Value Based On Expected 2015 Results?
- How Increased Focus On Pharmaceuticals In The Last 5 Years Has Helped J&J?
- By How Much Can J&J’s Revenue And EBITDA Grow Over The Next 3 Years?
- What Percentage Of Its Revenue Could J&J Lose Solely Due To Patent Losses Over The Next 5 Years?
Note: The figures mentioned are approximate values to help our readers remember and grasp the concept more intuitively. For accurate figures, please refer to our complete analysis for Johnson & Johnson
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)